A Phase 1/2 interventional study of Blinatumomab in Acute Lymphoblastic Leukemia, sponsored by Amgen Research (Munich) GmbH. Completed at 30 sites in 7 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-08.
Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 26th largest by enrollment, is the only one that started in 2012, is one of 8 in phase 1/2, and was the 4th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, France, Israel and 3 more countries
Ages 1–30
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1 mo–18 yrs
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 41 · Phase 3 14 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 67 across the 61 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amgen Research (Munich) GmbH, one of the names counted as Amgen. Under that name alone:
Amgen Research (Munich) GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen: 1 open now, 3 under way, 2 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen, this one is the 10th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 1/2, and was the 5th registered.
Amgen’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 2005.
11 of the studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT04722848Phase 3Gruppo Italiano Malattie EMatologiche dell'AdultoSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | 2027-09 |
| NCT06387121Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | 2026-12-01 |
| NCT03114865Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsA Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | 2026-12-30 |
| NCT05519579Northside Hospital, Inc.Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Among Amgen’s 20 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this dose of blinatumomab is effective.
Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow in which the bone marrow makes too many abnormal immature lymphocytes.
Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against cluster of differentiation (CD)19 expressing cells.
The purpose of this study is to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of escalating doses of blinatumomab in pediatric and adolescent patients with relapsed/refractory B-precursor ALL, to select a dose and to investigate the efficacy and safety of that dose of blinatumomab in the above-mentioned patient population.
The phase 1 part of the study included the evaluation of four dose levels of blinatumomab with comprehensive PK/PD assessments and was separated in 2 parts:
In the phase 2 extension cohort (efficacy phase) of the study, eligible participants less than 18 years were enrolled according to a two-stage design and received blinatumomab at the recommended dose level (5/15 μg/m²/day).
The study consisted of a screening period, a treatment period, and an End of Core Study visit 30 days after last dose of study medication. A treatment cycle consisted of a continuous intravenous (cIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks. Participants who achieved complete remission (CR) within 2 cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. Instead of consolidation cycles with blinatumomab, participants could be withdrawn from blinatumomab treatment to receive chemotherapy or allogeneic HSCT as early as the first cycle, at the discretion of the investigator.
After the last treatment cycle and End of Core Study visit, all participants were followed for efficacy and survival for up to 24 months after treatment start. Participants who suffered a hematological relapse of B-precursor ALL during their follow-up period (at least 3 months after completion of treatment) had the possibility for retreatment with blinatumomab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
disease:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
Biological: Blinatumomab
Administered by continuous intravenous infusion
Also known as: MT103, AMG103, BLINCYTO®
Phase I: Number of Participants With Dose-limiting Toxicities (DLTs)
The maximum tolerated dose (MTD) was defined as one or fewer out of 6 participants experiencing a dose limiting toxicity (DLT) or the maximum administered dose (MAD). A dose limiting toxicity is any Grade ≥ 3 adverse event related to study drug, Grade 3 fatigue, headache, insomnia, fever, hypotension or infection were not considered dose limiting toxicities. Laboratory parameters of Grade ≥ 3 but not considered as clinically relevant and/or responding to routine medical management, thrombocytopenia, leukopenia (including neutropenia and lymphopenia), and anemia were not considered dose limiting toxicities.
Time frame: Cycle 1, 28 days
Percentage of Participants With Complete Remission in the First Two Cycles
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central laboratory. Complete remission (CR) was defined as * M1 bone marrow (bone marrow blasts \< 5%) * No evidence of circulating blasts or extra-medullary disease Complete remission includes participants with incomplete recovery of peripheral blood counts.
Time frame: Cycles 1 and 2 (12 weeks)
Number of Participants With Adverse Events
The severity (or intensity) of adverse events (AEs) was assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v4.03 and according to the following: Grade 1 - Mild adverse event; Grade 2 - Moderate adverse event; Grade 3 - Severe and undesirable adverse event; Grade 4 - Life-threatening or disabling adverse event; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.
Time frame: From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 28 days
Steady State Concentration of Blinatumomab
Blinatumomab serum concentrations were quantified in all patients during the first 2 treatment cycles in the phase 1 part of the study only. Blinatumomab concentrations were quantified using a validated bioassay, the lower limit of quantification was 50 pg/mL. Steady state serum concentration (Css) was presumed on day 1, approximately 5 half-lives after the start of the IV infusion. The steady state serum concentration reported is the mean of the observed concentrations collected after during cycles 1 and 2.
Time frame: Cycles 1 and 2 during the IV infusion on day 3 (at least 48 hours after start of infusion) and days 8, 15 and 22 (steady state) and day 29 at End of Infusion (EoI) and 2, 4, and 8 hours after EoI for ages ≥ 2 years.
Time to Hematological Relapse (Duration of Response)
Time to hematological relapse was measured only for participants in remission and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death. Hematological relapse is defined as the proportion of blasts in bone marrow \> 25% following documented remission, or extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.
Time frame: Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.5 months for phase 2.
Overall Survival
Overall survival (OS) was measured for all participants from the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive. For patients who withdrew their informed consent only information until the date of withdrawal was analyzed. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan-Meier method.
Time frame: Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.6 months for phase 2.
Relapse-free Survival
Relapse-free survival (RFS) was assessed for participants who achieved a complete remission during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan-Meier method.
Time frame: Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.5 months for phase 2.
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission
The percentage of participants who received allogeneic hematopoietic stem cell transplantation (HSCT) while in remission due to treatment with blinatumomab during the first two cycles, and received no further anti-leukemic medication before HSCT.
Time frame: Up to the data cut-off date of 12 January 2015; Maximum duration on study was 24 months in phase 1 and 15 months for phase 2.
Number of Participants Who Developed Anti-blinatumomab Antibodies
Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.
Time frame: Predose up until 30 days after last dose of study medication; median treatment duration was 28 days.
Serum Cytokine Peak Levels
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-ɣ) using cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the lower limit of quantification (LLOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \< LOQ and \> LOD were reported as measured.
Time frame: Cycle 1 and 2 day 1 (prior to infusion, 2 and 6 hours after infusion start), day 2 and day 3.
The study was conducted in 26 centers in Germany, France, Italy, the Netherlands, the United Kingdom, and the United States of America. Results are reported for the primary analysis with a data cut-off date of 12 January 2015.
| Milestone | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|---|---|---|
| Started | 5 | 7 | 5 | 6 | 26 | 44 |
| Completed | 0 | 1 | 0 | 1 | 0 | 3 |
| Not completed | 5 | 6 | 5 | 5 | 26 | 41 |
| Withdrew: Hematopoietic stem cell transplantation | 2 | 2 | 1 | 0 | 5 | 3 |
| Withdrew: Lack of efficacy | 1 | 2 | 1 | 1 | 5 | 18 |
| Withdrew: Adverse event | 1 | 1 | 2 | 2 | 3 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 1 | 6 | 5 |
| Withdrew: Change of chemotherapy | 1 | 1 | 0 | 0 | 1 | 4 |
| Withdrew: Disease relapse | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 3 | 8 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 |
The maximum tolerated dose (MTD) was defined as one or fewer out of 6 participants experiencing a dose limiting toxicity (DLT) or the maximum administered dose (MAD). A dose limiting toxicity is any Grade ≥ 3 adverse event related to study drug, Grade 3 fatigue, headache, insomnia, fever, hypotension or infection were not considered dose limiting toxicities. Laboratory parameters of Grade ≥ 3 but not considered as clinically relevant and/or responding to routine medical management, thrombocytopenia, leukopenia (including neutropenia and lymphopenia), and anemia were not considered dose limiting toxicities.
| participants | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day |
|---|---|---|---|---|
| Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) | 0 | 1 | 2 | 1 |
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central laboratory. Complete remission (CR) was defined as * M1 bone marrow (bone marrow blasts \< 5%) * No evidence of circulating blasts or extra-medullary disease Complete remission includes participants with incomplete recovery of peripheral blood counts.
| percentage of participants | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Complete Remission in the First Two Cycles | 20.0 (0.5 to 71.6) | 42.9 (9.9 to 81.6) | 20.0 (0.5 to 71.6) | 33.3 (4.3 to 77.7) | 50.0 (29.9 to 70.1) | 31.8 (18.6 to 47.6) | 38.6 (27.2 to 51.0) |
The severity (or intensity) of adverse events (AEs) was assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v4.03 and according to the following: Grade 1 - Mild adverse event; Grade 2 - Moderate adverse event; Grade 3 - Severe and undesirable adverse event; Grade 4 - Life-threatening or disabling adverse event; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.
| participants | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day |
|---|---|---|---|---|---|
| Any adverse event (AE) | 5 | 7 | 70 | 6 | 5 |
| Adverse event of at least CTC grade 3 | 4 | 7 | 61 | 6 | 5 |
| Serious adverse event (SAEs) | 4 | 4 | 39 | 4 | 3 |
| SAE of at least grade 3 | 4 | 3 | 28 | 4 | 3 |
| AE leading to interruption of study drug | 0 | 0 | 10 | 2 | 2 |
| AE leading to discontinuation of study drug | 1 | 1 | 4 | 2 | 2 |
| Adverse event leading to death | 0 | 1 | 8 | 3 | 1 |
| Treatment-related adverse event (TRAE) | 5 | 6 | 59 | 5 | 5 |
| TRAE of at least CTC grade 3 | 4 | 5 | 38 | 4 | 5 |
| Treatment-related serious adverse event | 3 | 2 | 15 | 1 | 2 |
| TRAE leading to discontinuation of study drug | 1 | 1 | 2 | 1 | 2 |
| TRAE leading to death | 0 | 0 | 0 | 1 | 0 |
Blinatumomab serum concentrations were quantified in all patients during the first 2 treatment cycles in the phase 1 part of the study only. Blinatumomab concentrations were quantified using a validated bioassay, the lower limit of quantification was 50 pg/mL. Steady state serum concentration (Css) was presumed on day 1, approximately 5 half-lives after the start of the IV infusion. The steady state serum concentration reported is the mean of the observed concentrations collected after during cycles 1 and 2.
| pg/mL | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day |
|---|---|---|---|
| Cycle 1 (N = 27, 34, 7) | 162 ± 179 | 533 ± 392 | 1520 ± 1020 |
| Cycle 2 (N = 3, 13, 5) | 456 ± 288 | 866 ± 655 | 1150 ± 701 |
Time to hematological relapse was measured only for participants in remission and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death. Hematological relapse is defined as the proportion of blasts in bone marrow \> 25% following documented remission, or extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.
| months | Phase 1: Blinatumomab | Phase 2: Blinatumomab 5/15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|
| Time to Hematological Relapse (Duration of Response) | 10.3 (3.9 to 16.4) | 3.4 (1.7 to NA) | 5.2 (2.3 to 16.4) |
Overall survival (OS) was measured for all participants from the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive. For patients who withdrew their informed consent only information until the date of withdrawal was analyzed. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan-Meier method.
| months | Phase 1: Blinatumomab | Phase 2: Blinatumomab 5/15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|
| Overall Survival | 6.5 (3.6 to 10.6) | 8.2 (4.0 to 14.6) | 7.5 (4.0 to 11.8) |
Relapse-free survival (RFS) was assessed for participants who achieved a complete remission during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan-Meier method.
| months | Phase 1: Blinatumomab | Phase 2: Blinatumomab 5/15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|
| Relapse-free Survival | 7.9 (3.0 to 12.4) | 3.4 (1.7 to 13.9) | 4.4 (2.3 to 12.1) |
The percentage of participants who received allogeneic hematopoietic stem cell transplantation (HSCT) while in remission due to treatment with blinatumomab during the first two cycles, and received no further anti-leukemic medication before HSCT.
| percentage of participants | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission | 20.0 (0.5 to 71.6) | 28.6 (3.7 to 71.0) | 20.0 (0.5 to 71.6) | 16.7 (0.4 to 64.1) | 30.8 (14.3 to 51.8) | 11.4 (3.8 to 24.6) | 18.6 (10.3 to 29.7) |
Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.
| participants | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day |
|---|---|---|---|---|---|---|
| Number of Participants Who Developed Anti-blinatumomab Antibodies | 0 | 0 | 0 | 0 | 0 | 0 |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-ɣ) using cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the lower limit of quantification (LLOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \< LOQ and \> LOD were reported as measured.
| pg/mL | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day |
|---|---|---|---|
| IL-6: Cycle 1 Week 1 (N=31, 13, 5) | 4970 ± 17000 | 1780 ± 2620 | 23400 ± 24100 |
| IL-6: Cycle 2 Week 1 (N=4, 14, 5) | 526 ± 844 | 892 ± 2370 | 40.4 ± 68.0 |
| IL-10: Cycle 1 Week 1 (N=31, 13, 5) | 562 ± 710 | 1400 ± 2030 | 3170 ± 1720 |
| IL-10: Cycle 2 Week 1 (N=4, 14, 5) | 519 ± 497 | 432 ± 692 | 277 ± 308 |
| IFN-ɣ: Cycle 1 Week 1 (N=31, 13, 5) | 207 ± 516 | 539 ± 1240 | 2260 ± 1540 |
| IFN-ɣ: Cycle 2 Week 1 (N=4, 14, 5) | 51.8 ± 65.6 | 47.6 ± 51.5 | 22.8 ± 28.6 |
| IL-2: Cycle 1 Week 1 (N=31, 13, 5) | 22.7 ± 23 | 93.9 ± 150 | 900 ± 1390 |
| IL-2: Cycle 2 Week 1 (N=4, 14, 5) | 10.0 ± 0.00 | 14.3 ± 8.84 | 10.0 ± 0.00 |
| TNF-α: Cycle 1 Week 1 (N=31, 13, 5) | 87.3 ± 241 | 60.2 ± 127 | 285 ± 306 |
| TNF-α: Cycle 2 Week 1 (N=4, 14, 5) | 10.0 ± 0.00 | 10.0 ± 0.00 | 10.0 ± 0.00 |
| IL-4: Cycle 1 Week 1 (N=0, 0, 0) | NA ± NA | NA ± NA | NA ± NA |
| IL-4: Cycle 2 Week 1 (N=0, 0, 0) | NA ± NA | NA ± NA | NA ± NA |
Collected over From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 28 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Blinatumomab 5 µg/m²/Day | — | 4/5 (80%) | 5/5 (100%) |
| Phase 1: Blinatumomab 15 µg/m²/Day | — | 4/7 (57.1%) | 7/7 (100%) |
| Phase 1+2: Blinatumomab 5/15 µg/m²/Day | — | 39/70 (55.7%) | 70/70 (100%) |
| Phase 1: Blinatumomab 15/30 µg/m²/Day | — | 4/6 (66.7%) | 6/6 (100%) |
| Phase 1: Blinatumomab 30 µg/m²/Day | — | 3/5 (60%) | 5/5 (100%) |
| Total | — | 54/93 (58.1%) | 93/93 (100%) |
| Event | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Total |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/5 | 1/7 | 8/70 | 0/6 | 0/5 | 11/93 |
| Cytokine release syndromeImmune system disorders | 0/5 | 1/7 | 4/70 | 0/6 | 2/5 | 7/93 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/5 | 2/7 | 2/70 | 1/6 | 1/5 | 6/93 |
| Histiocytosis haematophagicBlood and lymphatic system disorders | 0/5 | 0/7 | 1/70 | 0/6 | 1/5 | 2/93 |
| Cardiac failureCardiac disorders | 0/5 | 0/7 | 0/70 | 0/6 | 1/5 | 1/93 |
| ColitisGastrointestinal disorders | 1/5 | 0/7 | 1/70 | 0/6 | 0/5 | 2/93 |
| Gastroenteritis viralInfections and infestations | 1/5 | 0/7 | 0/70 | 0/6 | 0/5 | 1/93 |
| OverdoseInjury, poisoning and procedural complications | 1/5 | 0/7 | 3/70 | 0/6 | 0/5 | 4/93 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/5 | 0/7 | 0/70 | 0/6 | 1/5 | 1/93 |
| ConvulsionNervous system disorders | 1/5 | 0/7 | 2/70 | 0/6 | 0/5 | 3/93 |
| Event | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1+2: Blinatumomab 5/15 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Total |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 4/5 | 7/7 | 54/70 | 4/6 | 5/5 | 74/93 |
| HeadacheNervous system disorders | 5/5 | 4/7 | 20/70 | 0/6 | 2/5 | 31/93 |
| AnaemiaBlood and lymphatic system disorders | 3/5 | 2/7 | 29/70 | 2/6 | 4/5 | 40/93 |
| HypertensionVascular disorders | 0/5 | 5/7 | 18/70 | 2/6 | 1/5 | 26/93 |
| Abdominal painGastrointestinal disorders | 3/5 | 3/7 | 13/70 | 0/6 | 1/5 | 20/93 |
| Blood bilirubin increasedInvestigations | 0/5 | 1/7 | 4/70 | 1/6 | 3/5 | 9/93 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/5 | 2/7 | 8/70 | 2/6 | 2/5 | 17/93 |
| Blood immunoglobulin G decreasedInvestigations | 0/5 | 4/7 | 1/70 | 0/6 | 0/5 | 5/93 |
| HypokalaemiaMetabolism and nutrition disorders | 0/5 | 4/7 | 15/70 | 3/6 | 0/5 | 22/93 |
| PainGeneral disorders | 1/5 | 2/7 | 6/70 | 3/6 | 0/5 | 12/93 |
| Age, Customized(participants) | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day | Total |
|---|---|---|---|---|---|---|---|
| < 2 years | 0 | 0 | 0 | 0 | 8 | 2 | 10 |
| 2 - 6 years | 3 | 5 | 2 | 4 | 9 | 11 | 34 |
| 7 - 17 years | 2 | 2 | 3 | 2 | 9 | 31 | 49 |
| Gender(Participants) | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 4 | 2 | 1 | 11 | 12 | 33 |
| Male | 2 | 3 | 3 | 5 | 15 | 32 | 60 |
| Race/Ethnicity, Customized(participants) | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day | Total |
|---|---|---|---|---|---|---|---|
| White | 5 | 7 | 5 | 5 | 22 | 33 | 77 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or other Pacific islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 1 | 3 | 5 | 9 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 6 | 7 |
| Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)(participants) | Phase 1: Blinatumomab 5 µg/m²/Day | Phase 1: Blinatumomab 15 µg/m²/Day | Phase 1: Blinatumomab 30 µg/m²/Day | Phase 1: Blinatumomab 15/30 µg/m²/Day | Phase 1: Blinatumomab 5/15 µg/m²/Day | Phase 2: Blinatumomab 5/15 µg/m²/Day | Total |
|---|---|---|---|---|---|---|---|
| Yes | 3 | 6 | 2 | 4 | 15 | 25 | 55 |
| No | 2 | 1 | 3 | 2 | 11 | 19 | 38 |
The record gives a start of Jan 2012, a primary completion of Aug 2014 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 2 years 6 months after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Amgen Research (Munich) GmbH →